KRRO Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
+ 1 more risk
Korro Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.31 |
| 52 Week High | US$98.00 |
| 52 Week Low | US$30.01 |
| Beta | 0 |
| 11 Month Change | -23.22% |
| 3 Month Change | 16.01% |
| 1 Year Change | 36.69% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 237.92% |
Recent News & Updates
Shareholder Returns
| KRRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.0% | 2.4% | 2.2% |
| 1Y | 36.7% | 16.2% | 31.7% |
Return vs Industry: KRRO exceeded the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: KRRO exceeded the US Market which returned 31.1% over the past year.
Price Volatility
| KRRO volatility | |
|---|---|
| KRRO Average Weekly Movement | 28.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KRRO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KRRO's weekly volatility has increased from 19% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 95 | Ram Aiyar | www.korrobio.com |
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates.
Korro Bio, Inc. Fundamentals Summary
| KRRO fundamental statistics | |
|---|---|
| Market cap | US$490.05m |
| Earnings (TTM) | -US$87.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs KRRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRRO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$87.81m |
| Earnings | -US$87.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KRRO perform over the long term?
See historical performance and comparison